> Millipore is buying Guava Technologies, a provider of bench top cell analysis systems, for $22.6 million. Guava reported sales of $22 million. Millipore release
> Aastrom BioSciences says it halted a mid-stage trial of its cardiac repair cell therapy after a patient suffered a 'serious adverse event.' In a release, Aastrom said that the event was related to erroneous "anesthesia management." Aastrom release
> Cambridge, MA-based Idera Pharmaceuticals says it has earned a $3.8 million milestone from Merck KGaA related to their collaboration on new cancer drugs. Release
> Astellas Pharma says it won't launch a hostile takeover of CV Therapeutics, adding that its bid for CV is its best offer. Story
> The FDA has approved Takeda's Kapidex, an oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease. Takeda release
> A hedge fund says it is preparing to nominate a board of directors to take control of Amylin Pharmaceuticals, which has seen its stock wither as doubts rise about its experimental diabetes drug. Report
> Germany's Cenix BioScience has inked a research deal to support Boehringer Ingelheim's drug discovery work. Cenix release
> Medarex will receive a milestone payment of $1 million from its partner, MedImmune, after the allowance of an IND application for MEDI-546, a fully human antibody that targets a component of the type 1 interferon pathway. Medarex release
> Cephalon says it is exercising its option to license worldwide rights to Lupuzor, an investigational medication for the treatment of Systemic Lupus Erythematosus. Cephalon will pay ImmuPharma a one-time license fee of $30 million. Release
> Just as Pfizer's bid for Wyeth prompted all sorts of chatter, so has Roche's new-and-lower offer for the 44 percent of Genentech it doesn't already own. Report
And Finally... The fact that pharma's employment numbers are falling hasn't been lost on British Prime Minister Gordon Brown. The PM has assembled a special panel to figure out how to protect pharma and biotech companies as the economy deteriorates. UK report